Arthur Paullin
Long only, medium-term horizon, dividend investing, master limited partnerships

Dynavax Technologies - DVAX And Nothing But DVAX

This article is in response to the press release of June 10, 2013 from Dynavax (NASDAQ:DVAX) regarding ongoing discussions with the FDA and the pros and cons of potential courses of action by current investors together with the author's conclusion.


Dynavax is a clinical-stage bio-pharmaceutical company with an under development product named "Heplisav" , a vaccine for the prevention of Hepatitis B. In November, 2012, the company received the FDA's advisory committee's report and in February of this year received an answer from the FDA that it agreed with the -committee. Basically, it stated that a wider study of the safety of the vaccine was required. At the same time they agreed that the vaccine was superior...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details